Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 1460-1471, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (43)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moyer, T. P.
Right arrow Articles by Hurt, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moyer, T. P.
Right arrow Articles by Hurt, R. D.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2002;48:1460-1471.)
© 2002 American Association for Clinical Chemistry, Inc.

Simultaneous Analysis of Nicotine, Nicotine Metabolites, and Tobacco Alkaloids in Serum or Urine by Tandem Mass Spectrometry, with Clinically Relevant Metabolic Profiles

Thomas P. Moyer1a, Joel R. Charlson1, Robert J. Enger1, Lowell C. Dale2, Jon O. Ebbert2, Darrell R. Schroeder3 and Richard D. Hurt2

1 Drug Laboratory, Department of Laboratory Medicine & Pathology,
2 Nicotine Dependence Center, Department of Internal Medicine, and
3 Biostatistics Department, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905.

aAddress correspondence to this author at: Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN 55905. E-mail moyer.thomas{at}mayo.edu.

Background: Assessment of nicotine metabolism and disposition has become an integral part of nicotine dependency treatment programs. Serum nicotine concentrations or urine cotinine concentrations can be used to guide nicotine patch dose to achieve biological concentrations adequate to provide the patient with immediate relief from nicotine withdrawal symptoms, an important factor in nicotine withdrawal success. Absence of nicotine metabolites and anabasine can be used to document abstinence from tobacco products, an indicator of treatment success.

Methods: The procedure was designed to quantify nicotine, cotinine, trans-3'-hydroxycotinine, anabasine, and nornicotine in human serum or urine. The technique required simple extraction of the sample with quantification by HPLC–tandem mass spectrometry.

Results: The procedure for simultaneous analysis of nicotine, its metabolites, and tobacco alkaloids simultaneously quantified five different analytes. Test limit of quantification, linearity, imprecision, and accuracy were adequate for clinical evaluation of patients undergoing treatment for tobacco dependency. The test readily distinguished individuals who had no exposure to tobacco products from individuals who were either passively exposed or were abstinent past-tobacco users from those who were actively using a tobacco or nicotine product.

Conclusions: Nicotine, cotinine, trans-3'-hydroxycotinine, nornicotine, and anabasine can be simultaneously and accurately quantified in either serum or urine by HPLC–tandem mass spectrometry with imprecision <10% at physiologic concentrations and limits of quantification ranging from 0.5 to 5 µg/L. Knowledge of serum or urine concentrations of these analytes can be used to guide nicotine replacement therapy or to assess tobacco abstinence in nicotine dependency treatment. These measurements are now an integral part of the clinical treatment and management of patients who wish to overcome tobacco dependence.




The following articles in journals at HighWire Press have cited this article:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
N. J. Montalto and W. O. Wells
Validation of Self-Reported Smoking Status Using Saliva Cotinine: A Rapid Semiquantitative Dipstick Method
Cancer Epidemiol. Biomarkers Prev., September 1, 2007; 16(9): 1858 - 1862.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Vassallo, K. Tamada, J. S. Lau, P. R. Kroening, and L. Chen
Cigarette Smoke Extract Suppresses Human Dendritic Cell Function Leading to Preferential Induction of Th-2 Priming
J. Immunol., August 15, 2005; 175(4): 2684 - 2691.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
X. Xu, M. M. Iba, and C. P. Weisel
Simultaneous and Sensitive Measurement of Anabasine, Nicotine, and Nicotine Metabolites in Human Urine by Liquid Chromatography-Tandem Mass Spectrometry
Clin. Chem., December 1, 2004; 50(12): 2323 - 2330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. D. Kellogg, J. Behaderovic, O. Bhalala, and N. Rifai
Rapid and Simple Tandem Mass Spectrometry Method for Determination of Serum Cotinine Concentration
Clin. Chem., November 1, 2004; 50(11): 2157 - 2159.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.